GT Biopharma (GTBP) Long-Term Deferred Tax (2015 - 2019)
GT Biopharma (GTBP) posted quarterly Long-Term Deferred Tax of $96.6 million for Q4 2019, up 76545.24% quarter-over-quarter from $126000.0 in Q2 2018.
GT Biopharma (GTBP) Long-Term Deferred Tax (2015 - 2019) Analysis & Trends
GT Biopharma (GTBP) has reported Long-Term Deferred Tax for 5 consecutive years, with $96.6 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Long-Term Deferred Tax changed N/A year-over-year to $96.6 million; the TTM figure through Dec 2019 stood at $96.6 million (changed N/A YoY), while the FY2019 annual figure was $96.6 million, changed N/A from the prior year.
- Long-Term Deferred Tax improved to $96.6 million in Q4 2019 per GTBP's latest filing, from $126000.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $96.6 million in Q4 2019 and bottomed at $126000.0 in Q2 2018.
- Historically, Long-Term Deferred Tax has averaged $25.0 million across 5 years, with a median of $15.7 million in 2015.
- Annual changes were most pronounced in 2016 — Long-Term Deferred Tax soared 39.23% — and 2017, when it fell 25.62%.
- GT Biopharma's Long-Term Deferred Tax stood at $15.4 million in 2015, then surged by 39.23% to $21.4 million in 2016, then dropped by 25.62% to $15.9 million in 2017, then slumped by 99.21% to $126000.0 in 2018, then surged by 76545.24% to $96.6 million in 2019.
- Business Quant data shows GTBP's Long-Term Deferred Tax at $96.6 million in Q4 2019, $126000.0 in Q2 2018, and $670000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 96.57 Mn |
| Jun 30, 2018 | 126,000.00 |
| Mar 31, 2018 | 670,000.00 |
| Dec 31, 2017 | 15.95 Mn |
| Dec 31, 2016 | 21.44 Mn |
| Dec 31, 2015 | 15.40 Mn |